Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

The development of heterologous prime-boost regimens utilizing Bacille Calmette–Guerin (BCG) as the priming vaccine is a promising approach to improve the efficacy of vaccination against tuberculosis (TB). In this study, we examined the ability of a DNA vaccine that expressed a fusion of antigens Rv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Juan, Hu, Zhidong, Lu, Shui-Hua, Fan, Xiao-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577005/
https://www.ncbi.nlm.nih.gov/pubmed/36267175
http://dx.doi.org/10.3389/fmicb.2022.927031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577005/
https://www.ncbi.nlm.nih.gov/pubmed/36267175
http://dx.doi.org/10.3389/fmicb.2022.927031

Ejemplares similares